Innate Pharma S.A.(IPHA)Earnings, Financials & Key Ratios
IPHA•NASDAQ
$1.79
Price updated Jun 27, 2026
AboutInnate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.Show more
- Revenue$3M-77.9%
- EBITDA-$48M+2.5%
- Net Income-$49M+0.6%
- EPS (Diluted)-0.53+13.1%
- Gross Margin100%
- EBITDA Margin-1734.27%-341.5%
- Operating Margin-1916.94%-369.1%
- Net Margin-1764.51%-350.2%
IPHA Price & Volume
Innate Pharma S.A. (IPHA) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependency Drives Persistent Structural Financial Distress
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial dependency
"Innate Pharma faces a precarious outlook characterized by extreme revenue volatility, as evidenced by a 77.92% year-over-year decline in top-line performance driven by reliance on sporadic milestone payments. The company's inability to achieve consistent operating leverage, coupled with a negative equity position of $21.7 million, suggests significant liquidity risks that may necessitate dilutive financing. Investors should monitor the company's ability to secure new partnership agreements, as the current $28.1 million cash balance provides a limited runway for ongoing R&D commitments."
Verdict Logic
the company's reliance on binary clinical outcomes and a dwindling cash reserve of $28.1 million creates an unfavorable risk-reward profile for long-term investors.
IPHA Growth Metrics
Innate Pharma S.A. (IPHA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-16.97%
5 Years-47.48%
3 Years-63.58%
TTM-84.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-49.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-41.03%
Return on Capital
10 Years-23.77%
5 Years-42.6%
3 Years-53.09%
Last Year-102.61%
IPHA Recent Earnings
Innate Pharma S.A. (IPHA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (25%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.35-116.4%
$0.16
Rev
$5M-16.1%
$6M
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.35+0.8%
$0.35
Rev
$5M+75.8%
$3M
Q4 2025
Sep 17, 2025Metric
Actual
Est
EPS
$0.29-106.5%
$0.14
Rev
$6M+192.0%
$2M
Q2 2025
May 12, 2025Metric
Actual
Est
EPS
$0.32-18.3%
$0.27
Rev
$285,795-98.4%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.35vs $0.16-116.4% | $5Mvs $6M-16.1% |
| Q2 2026 | Mar 26, 2026 | $0.35vs $0.35+0.8% | $5Mvs $3M+75.8% |
| Q4 2025 | Sep 17, 2025 | $0.29vs $0.14-106.5% | $6Mvs $2M+192.0% |
| Q2 2025 | May 12, 2025 | $0.32vs $0.27-18.3% | $285,795vs $18M-98.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Innate Pharma S.A. (IPHA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.79 | $168.09M | -2.96 | -77.92% | -1764.51% | — | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $0.31 | $60.51M | -0.54 | -13.43% | -299.66% | — | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $37.90 | $2.25B | -5.32 | 48.03% | -639.84% | -34.11% | — |
Compare IPHA vs Peers
Innate Pharma S.A. (IPHA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when IPHA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IPHA Frequently Asked Questions
Innate Pharma S.A. (IPHA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Innate Pharma S.A.'s revenue?
Innate Pharma S.A. (IPHA) reported $15.4M in revenue for fiscal year 2025. This represents a 1085% increase from $1.3M in 2005.
How fast is Innate Pharma S.A. growing?
Innate Pharma S.A. (IPHA) saw revenue decline by 77.9% over the past year.
Is IPHA profitable?
Innate Pharma S.A. (IPHA) reported a net loss of $98.4M for fiscal year 2025.
Dividend & Returns
What is Innate Pharma S.A.'s free cash flow?
Innate Pharma S.A. (IPHA) had negative free cash flow of $64.9M in fiscal year 2025, likely due to heavy capital investments.